4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
Key Takeaways
Infertility is clinically defined as the failure to achieve clinical pregnancy after 12 months of regular, unprotected sexual intercourse in women under age 35, or after 6 months in women aged 35 years and older; immediate evaluation is warranted for patients aged >=40, or with oligomenorrhea, known endometriosis, or pelvic inflammatory disease.
The initial diagnostic evaluation addresses the essential triad: male factor assessment via semen analysis, ovulatory confirmation via mid-luteal serum progesterone (>3 ng/mL confirms ovulation), and anatomical assessment of tubal patency and uterine contour via hysterosalpingography (HSG) performed during cycle days 7–10.
Semen analysis interpretation follows the WHO 6th edition lower reference limits: volume >=1.4 mL, sperm concentration >=16 million/mL, total motility >=42%, progressive motility >=30%, and strict Kruger normal morphology >=4%.
Ovarian reserve testing integrates cycle-independent anti-Müllerian hormone (AMH; <1.0 ng/mL indicates diminished reserve), early follicular antral follicle count (AFC; <5–7 indicates diminished reserve), and cycle day 3 FSH and estradiol.
First-line ovulation induction for anovulatory PCOS is the aromatase inhibitor letrozole (superior live-birth and lower multiple gestation rates compared to clomiphene citrate); assisted reproductive technologies (IUI, IVF, ICSI, PGT) address refractory and structural etiologies, requiring vigilant monitoring for ovarian hyperstimulation syndrome (OHSS).
Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
Infertility affects approximately 1 in 6 couples globally. Modern clinical practice emphasizes an evidence-based, rapid diagnostic workup that evaluates male, ovulatory, and anatomical factors concurrently before initiating targeted medical, surgical, or assisted reproductive interventions.
Important
Both partners must be evaluated concurrently from the onset. Because male factor subfertility contributes to 40% to 50% of cases, a non-invasive semen analysis is mandatory at the initial visit before embarking on invasive female procedures.
Clinical Definitions & Evaluation Timelines
The American Society for Reproductive Medicine (ASRM) and ACOG establish age-stratified thresholds reflecting the natural decline in female fecundability (monthly probability of conceiving):
- Women Under 35 Years: Evaluation begins after 12 months of regular, unprotected intercourse without conception (normal fecundability is 20%–25% per cycle; ~85% conceive within 12 months).
- Women Aged 35 to 39 Years: Evaluation begins after 6 months of unprotected intercourse, reflecting accelerated oocyte atresia and declining oocyte quality.
- Women Aged 40 Years and Older: Immediate evaluation and specialist referral upon presentation, as fecundability drops to <5% per cycle with high miscarriage risk.
- Immediate Evaluation at Any Age:
- Oligomenorrhea or amenorrhea.
- Known/suspected uterine, tubal, or pelvic peritoneal disease (history of stage III–IV endometriosis, prior pelvic inflammatory disease [PID], ectopic pregnancy, pelvic tuberculosis, ruptured appendicitis).
- Prior pelvic radiation, gonadotoxic chemotherapy, or ovarian surgery.
- Known subfertile male partner (cryptorchidism, mumps orchitis, varicocele).
Etiologic Distribution
Male factor accounts for 35%–40% (sole cause in 20%–30%; contributory in 10%–20%); Ovulatory dysfunction 25%–30%; Tubal/pelvic pathology 20%–25%; Uterine/cervical factors 3%–5%; and Unexplained infertility 15%–20%.
The Essential Diagnostic Triad
A comprehensive evaluation simultaneously assesses the sperm, the egg, and the transport conduit.
1. Male Factor Assessment: Semen Analysis
Specimen is collected by masturbation after 2 to 7 days of sexual abstinence and analyzed within 60 minutes.
- If abnormal, perform a confirmatory repeat analysis 2 to 4 weeks later (spermatogenesis takes ~74 days; transient illness or heat exposure can temporarily impair parameters).
| Semen Parameter | WHO 6th Edition Lower Reference Limit (5th Percentile) | Classification if Subnormal |
|---|---|---|
| Semen Volume | >= 1.4 mL | Hypospermia (<1.4 mL) or Aspermia (0 mL) |
| Total Sperm Count | >= 39 million per ejaculate | Oligozoospermia (<39 million/ejaculate) |
| Sperm Concentration | >= 16 million/mL | Oligozoospermia (<16 million/mL) |
| Total Motility (PR + NP) | >= 42% | Asthenozoospermia (<42% total motility) |
| Progressive Motility (PR) | >= 30% | Asthenozoospermia (<30% progressive) |
| Vitality (Live Sperm) | >= 54% | Necrozoospermia (<54% viable) |
| Morphology (Kruger Strict) | >= 4.0% normal forms | Teratozoospermia (<4.0% normal forms) |
| Leukocyte Concentration | < 1.0 million/mL | Leukocytospermia (>=1.0 M/mL, suggests infection) |
Note
Complete absence of sperm is azoospermia. Differentiate obstructive azoospermia (normal testicular size, normal FSH; e.g., congenital bilateral absence of vas deferens [CBAVD, test CFTR gene]) from non-obstructive azoospermia (testicular failure, elevated FSH; e.g., Klinefelter syndrome 47,XXY, Y-chromosome microdeletions).
2. Ovulatory Factor Assessment
- Mid-Luteal Phase Serum Progesterone: Drawn 7 days prior to expected menses (Day 21 of a 28-day cycle, or Day 28 of a 35-day cycle). A value >3 ng/mL confirms recent ovulation and corpus luteum formation; >10 ng/mL demonstrates robust luteal progesterone production in an unmedicated cycle.
- Urinary LH Detection Kits: Detects the urinary LH surge preceding ovulation by 24 to 36 hours.
- Basal Body Temperature (BBT): Progesterone-induced biphasic shift (0.4°F–0.8°F / 0.2°C–0.4°C rise) confirms ovulation retrospectively.
3. Anatomical & Tubal Patency Assessment
- Hysterosalpingography (HSG): Fluoroscopic exam with cervical instillation of radiopaque iodinated contrast to visualize the uterine cavity contour and tubal patency.
- Timing: Scheduled strictly in the early follicular phase (cycle days 7 to 10), after menstrual bleeding ceases but prior to ovulation. This ensures a thin endometrium for visualization, avoids disrupting an unrecognized luteal pregnancy, and lowers infection risk.
- Findings: Free peritoneal spill confirms patency. Identifies proximal occlusion or distal hydrosalpinx. Oil-soluble contrast medium (OSCM) provides therapeutic benefit by dislodging intratubal mucous plugs.
- Saline Infusion Sonohysterography (SIS): Superior to HSG for intracavitary pathology (submucosal fibroids, polyps, synechiae).
- Laparoscopy with Chromopertubation: Gold standard for direct peritoneal visualization, adhesiolysis, and endometriosis resection.
Ovarian Reserve Testing (ORT)
ORT evaluates follicular pool quantity, not oocyte genetic quality (which is dictated by maternal age).
- Anti-Müllerian Hormone (AMH):
- Secreted by granulosa cells of preantral and small antral follicles (2–8 mm).
- Cycle-Independent: Can be drawn on any day of the menstrual cycle.
- Normal: 1.0 to 3.5 ng/mL. <1.0 ng/mL indicates Diminished Ovarian Reserve (DOR) (<0.5 ng/mL reflects severe depletion). >3.5 to 4.0 ng/mL suggests PCOS and flags elevated risk for Ovarian Hyperstimulation Syndrome (OHSS).
- Antral Follicle Count (AFC): Early follicular transvaginal ultrasound summing all 2–10 mm follicles. An AFC <5 to 7 total follicles indicates DOR; >20 indicates polycystic morphology.
- Day 3 Serum FSH & Estradiol: Drawn cycle day 2–4. As ovarian reserve shrinks, declining inhibin B causes day 3 FSH to rise (>10 to 12 IU/L). An elevated day 3 estradiol (>60–80 pg/mL) from premature follicular recruitment artificially suppresses FSH into the normal range (false-negative FSH).
Ovulation Induction Pharmacotherapy
- Letrozole (Femara) — First-Line for PCOS:
- Mechanism: Non-steroidal aromatase inhibitor that selectively blocks CYP19A1, suppressing estrogen synthesis. Decreased negative feedback increases pituitary FSH release, driving monofollicular growth.
- Dosing: 2.5 to 7.5 mg daily for 5 days starting on cycle day 3, 4, or 5.
- Clinical Advantage: Established as the first-line agent for anovulatory PCOS by the PPCOS II trial (higher live-birth rates [27.5% vs 19.1%], higher ovulation rates, faster conception, and lower multiple pregnancy rates than clomiphene). Does not deplete peripheral estrogen receptors, preserving endometrial thickness (>=8 mm) and cervical mucus.
- Clomiphene Citrate (Clomid): Selective Estrogen Receptor Modulator (SERM) that depletes hypothalamic estrogen receptors, stimulating GnRH and FSH/LH pulses. Dosed 50 to 150 mg daily for 5 days starting cycle day 3 or 5. Adverse effects include hot flashes, mood lability, visual scotomas (mandates stopping), and anti-estrogenic endometrial thinning (<7 mm) in up to 30% of cycles.
- Exogenous Gonadotropins: Injectable rFSH or hMG for oral agent failure or IVF. Carries high risk of multifollicular development, high-order multiple gestations, and OHSS; requires close ultrasound and estradiol monitoring.
Assisted Reproductive Technologies (ART) & Complications
- Intrauterine Insemination (IUI): Washed, concentrated motile sperm placed into the uterine fundus via catheter at ovulation (triggered by hCG 36 hours prior). Used for mild male subfertility, cervical factor, donor sperm, and unexplained infertility. Requires at least one patent tube and adequate motile sperm (>5–10 million).
- In Vitro Fertilization (IVF): Controlled ovarian hyperstimulation, ultrasound-guided transvaginal oocyte retrieval under sedation, laboratory fertilization, blastocyst culture (day 5), and embryo transfer. Indicated for tubal obstruction, severe male factor, diminished reserve, advanced maternal age, and failed IUI.
- Intracytoplasmic Sperm Injection (ICSI): Direct microinjection of a single sperm into a mature metaphase II oocyte. Standard for severe male factor infertility (severe oligoasthenoteratozoospermia, surgically retrieved sperm via TESE).
- Preimplantation Genetic Testing (PGT): Biopsy of day-5 blastocysts for aneuploidy (PGT-A), monogenic single-gene disorders (PGT-M), or structural rearrangements (PGT-SR).
- Complications:
- Ovarian Hyperstimulation Syndrome (OHSS): Triggered by hCG; massive ovarian VEGF secretion causes widespread capillary hyperpermeability. Intravascular fluid shifts into third spaces, causing ascites, pleural effusions, hemoconcentration (hematocrit >45%–55%), oliguria, and thromboembolism. Prevented by GnRH agonist trigger, cabergoline, and "freeze-all" strategies.
- Multiple Gestations: Elective Single Embryo Transfer (eSET) at the blastocyst stage is the standard of care to achieve singleton pregnancies and avoid prematurity risks.
A 31-year-old nulligravida presents with her 32-year-old male partner for an initial infertility consultation. They have been having regular, unprotected intercourse for 14 months without achieving pregnancy. The female partner has regular 28-day menstrual cycles. A semen analysis collected after 3 days of abstinence reveals: volume 2.2 mL, sperm concentration 22 million/mL, total motility 52%, progressive motility 38%, and Kruger strict normal morphology 1.5% (reference lower limit >=4.0%). The remaining semen parameters are normal. Which of the following is the correct diagnosis for the male partner?
Oligozoospermia
Asthenozoospermia
Teratozoospermia
Azoospermia
A 36-year-old female presents for evaluation after failing to conceive for 7 months of unprotected intercourse. Her menstrual cycles are regular every 27 to 29 days. As part of her initial infertility evaluation, she is scheduled for a hysterosalpingography (HSG) to assess tubal patency and uterine cavity architecture. At which point in her menstrual cycle should this diagnostic imaging procedure be scheduled?
During active menstrual flow (cycle days 1 to 3) to allow contrast to pass easily through the dilated cervix
In the early follicular phase (cycle days 7 to 10) after menstrual bleeding has ceased but prior to ovulation
At the time of the mid-cycle LH surge (cycle days 13 to 15) to evaluate periovulatory tubal motility
In the mid-luteal phase (cycle days 21 to 23) to assess secretory endometrial thickness and implantation receptivity
A 29-year-old woman with polycystic ovary syndrome (PCOS) and anovulatory infertility presents to discuss medical therapy to achieve pregnancy. She has regular sexual intercourse with a partner whose semen analysis is completely normal. An HSG confirms bilateral tubal patency and a normal endometrial cavity. Which medication is the guideline-recommended first-line pharmacologic agent for ovulation induction in this patient?
Letrozole (aromatase inhibitor)
Clomiphene citrate (selective estrogen receptor modulator)
Exogenous human menopausal gonadotropins (hMG)
Metformin monotherapy
Sections you finish are checked off in the contents.